NEW YORK, August 19, 2026, 04:20 EDT
- Heidi Overton has been chosen by Trump to head the FDA, according to Reuters.
- Sarepta has two pending applications following a confirmatory trial that did not achieve its primary endpoint.
- SRPT finished trading at $18.02 on August 18, with analyst price targets ranging from $5 to $38.
Sarepta Therapeutics NASDAQ:SRPT will undergo another regulatory hurdle as President Donald Trump tapped White House adviser Heidi Overton to head the Food and Drug Administration, a source told Reuters. Overton’s nomination is still awaiting Senate approval. Both the White House and the FDA had not responded to Reuters at the time of publication.
Sarepta’s leadership change carries greater significance compared to many other pharmaceutical firms. The company’s filings for AMONDYS 45 and VYONDYS 53 are for full approval, although the ESSENCE trial did not meet its main goal. Sarepta is urging authorities to consider numerical patterns, additional analysis, and data from actual patient use.
| Regulatory item | Current status | Investor relevance |
|---|---|---|
| AMONDYS 45 sNDA | Received; decision scheduled for February 28, 2027 | Aims to secure full approval |
| VYONDYS 53 sNDA | Received; decision scheduled for February 28, 2027 | Relies on identical submission and timing |
| ESSENCE Phase 3 | Main outcome was not achieved | Heightens importance of regulator evaluation |
| ELEVIDYS | U.S. approval is limited to ambulatory use | Limits the eligible patient population |
The FDA acknowledged receipt of both supplemental applications on June 30. Sarepta reported that over 1,800 patients globally have been treated with its exon-skipping therapies. The company also noted that ongoing approval may be contingent on confirmation of clinical benefit.
Sarepta shares ended the session at $18.02 on August 18, a decrease of 0.88%. The price placed the stock in the lower segment of its 52-week range between $14.69 and $25.32. The company’s market capitalisation stood at roughly $1.90 billion.
| Q2 metric | 2026 | 2025 | Change |
|---|---|---|---|
| Total revenue | $401.3 million | $611.1 million | -34% |
| Net product revenue | $328.7 million | Not compared separately here | — |
| GAAP operating income | $13.3 million | $115.6 million | -89% |
| Non-GAAP operating income | $86.5 million | $162.8 million | -47% |
| GAAP net income/(loss) | ($4.9 million) | $196.9 million | Not considered meaningful |
Product revenue in the second quarter consisted of $230.6 million from PMO therapies and $98.1 million from ELEVIDYS. Overall revenue declined due to ELEVIDYS being indicated solely for ambulatory patients and the absence of a Roche milestone payment received a year earlier. Cash and investments totaled roughly $945 million as of June 30.
Sarepta adjusted its net product revenue forecast for 2026 to a range of $1.2 billion-$1.3 billion, compared with its prior estimate of $1.2 billion-$1.4 billion. Newly appointed CEO Michael Severino stated the company needs to “execute our commercial strategy” and manage capital allocation carefully. Company results and quotation
Analysts remain split on the stock. According to Google Finance, out of 16 analysts surveyed over the past three months, five rate it Buy, seven recommend Hold, and four suggest Sell. The consensus price target stands at $22.87, which is 26.9% higher than the closing price on Tuesday.
| Analyst / firm | Recommendation | Target | Date |
|---|---|---|---|
| Yanan Zhu / Wells Fargo | Buy | $38 | August 6, 2026 |
| Kostas Biliouris / Oppenheimer | Buy | $35 | August 6, 2026 |
| Eliana Merle / Barclays | Hold | $20 | August 7, 2026 |
| Gavin Clark-Gartner / Evercore ISI | Hold | $19 | August 10, 2026 |
| Tazeen Ahmad / Bank of America | Sell | $18 | August 6, 2026 |
| Mitchell Kapoor / H.C. Wainwright | Sell | $5 | August 6, 2026 |
The primary signal for investors is the $5-to-$38 target range. Sarepta’s applications would not be determined by a formal nomination. However, the process may influence staffing levels, review priorities, and how readily the FDA considers real-world evidence for rare disease treatments.
Sarepta declined roughly 2.0% from the close on August 12 to the close on August 18. U.S. markets are currently shut. The upcoming trading session will indicate if investors interpret Overton’s appointment as a shift in rare-disease policy or simply as a staffing decision.
In the coming week, attention will focus on two imminent events. Investors are set to monitor an official announcement from the White House along with initial response from the Senate. Commentary from the FDA regarding accelerated approval, real-world evidence, or personnel matters would be particularly significant for SRPT.
Risks: Overton’s nomination or confirmation may not occur. Should Overton be confirmed, statutory standards and career reviewer oversight remain as limitations on policy shifts. Sarepta continues to encounter risks related to safety, labeling, commercial execution, and clinical evidence, independent of changes in FDA leadership.
Related articles: Pharmaceuticals
Sarepta Therapeutics
Regulatory discretion is the valuation hinge.
Where the stock sits
The close was 22.7% above the low and 28.8% below the high.
Analyst split
Q2 2026 revenue mix
Total revenue: $401.3M, down 34% year over year. Net product revenue: $328.7M.
Regulatory clock
FDA accepts AMONDYS 45 and VYONDYS 53 supplemental applications.
Reuters reports Trump selected Heidi Overton to lead the FDA.
Target action date for both traditional-approval decisions.
Recommendation range shows binary risk
| Firm | View | Target | Date |
|---|---|---|---|
| Wells Fargo | Buy | $38 | Aug 6 |
| Oppenheimer | Buy | $35 | Aug 6 |
| Evercore ISI | Hold | $19 | Aug 10 |
| Bank of America | Sell | $18 | Aug 6 |
| H.C. Wainwright | Sell | $5 | Aug 6 |
